Halozyme Announces Approval of Roche's Tecentriq® Subcutaneous (SC) with ENHANZE® in Great BritainPRNewsWire • 08/29/23
Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Top EstimatesZacks Investment Research • 08/08/23
Halozyme Therapeutics (HALO) Soars 5.4%: Is Further Upside Left in the Stock?Zacks Investment Research • 07/18/23
Positive Topline Data Reported from argenx's ADHERE Study of VYVGART® Hytrulo with Halozyme's ENHANZE® Drug Delivery Technology in Patients with Chronic Inflammatory Demyelinating PolyneuropathyPRNewsWire • 07/17/23
Positive Results Announced from Phase 3 OCARINA II Trial Evaluating Roche's OCREVUS® (ocrelizumab) with Halozyme's ENHANZE® Drug Delivery Technology in Patients with Multiple SclerosisPRNewsWire • 07/13/23
Halozyme: Inflection Point With argenx's Vyvgart SC Approval (Reiterating Buy)Seeking Alpha • 07/05/23
Halozyme Announces argenx Receives FDA Approval for VYVGART® Hytrulo With ENHANZE® for Subcutaneous Use in Generalized Myasthenia GravisPRNewsWire • 06/20/23
Halozyme Therapeutics: Pharma With Growing Royalty Revenue And Product IncomeSeeking Alpha • 06/19/23
Halozyme Therapeutics (HALO) Up 0.7% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 06/08/23
Halozyme to Present at the Goldman Sachs 44th Annual Global Healthcare ConferencePRNewsWire • 06/06/23
Halozyme Therapeutics (HALO) Q1 Earnings and Revenues Miss EstimatesZacks Investment Research • 05/09/23
Strength Seen in Halozyme Therapeutics (HALO): Can Its 5.3% Jump Turn into More Strength?Zacks Investment Research • 03/21/23